RCT of Iodine-containing MNPs vs Oral Iodized Oil to Prevent Iodine Deficiency in Weaning Infants

NCT ID: NCT02421653

Last Updated: 2017-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, two intervention strategies to address iodine deficiency and prevent iodine deficiency disorders in breast-fed weaning infants will be evaluated in a mild to moderate iodine-deficient population in Zamboanga del Norte, Philippines, Southeast Asia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Universal salt iodization (USI) is the most effective means to ensure optimal population iodine status and prevent iodine deficiency. In countries where USI is well implemented it is generally assumed that iodine requirements of infants are covered through breast milk. As infants wean from breast milk, at the age of 4-6 months, iodized salt programs likely contribute little to their iodine intakes. Home-prepared complementary foods have low native iodine content and pediatric guidelines recommend no extra salt be given to infants during the first year making the dietary sources of iodine limited. Weaning infants may therefore be particularly vulnerable to iodine deficiency and its effects.

Iodine is an essential micronutrient and an integral component of the thyroid hormones, needed for normal growth and development, particularly of the brain. Thyroid hormones play a critical role for development of the central nervous system from early fetal life until well after birth. Thyroid hormone insufficiency during postnatal development is associated with sensorimotor and language deficits and hypothyroidism in infancy is associated with poorer language, memory skills, fine motor, auditory processing, attention and executive processing.

In iodine deficient areas where iodized salt coverage is poor, WHO, UNICEF and the International Council for the Control of Iodine Deficiency Disorders (ICCIDD) recommend infants between 7 and 24 months be given a daily dose of 90 µg iodine (potassium iodate) or an annual dose of 200 mg iodine (iodised oil). The scientific evidence for this recommendation is weak, however, and it is uncertain under what conditions the two prevention strategies may be applied and which of the two is best when.

The objective of this study is to evaluate the efficacy and safety of the two recommended intervention strategies in iodine-deficient weaning infants. The need for high-quality controlled studies to better understand the potential contribution and synergy of alternative strategies to help achieve optimal iodine nutrition in different population groups and settings has recently been defined as a major research priority.

Following a cross-sectional, pilot study, we will conduct a randomized controlled trial to assess the efficacy of two daily doses of iodine as potassium iodate (90 µg, 100% of the WHO recommended dose, and 45 µg, 50% of the WHO recommended dose) and the annual dose of 200 mg iodine in iodised oil, via a randomized, controlled trial in weaning infants of lactating mothers living in an area affected by mild to moderate iodine deficiency in Zamboanga del Norte, Philippines, Southeast Asia.

We will compare the efficacy of each of the iodine doses against each other, and against micro-nutrients given alone, estimate the optimal level of iodine for inclusion in MNPs, and report on the safety of these interventions in weaning infants.

This study will provide important guidance to public health experts, governments and international organisations to ensure normal infant thyroid function and growth and development.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iodine Deficiency Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MNP90 + INERT OIL

Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;

Group Type EXPERIMENTAL

MNP90

Intervention Type DIETARY_SUPPLEMENT

90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

INERT OIL

Intervention Type DIETARY_SUPPLEMENT

Non-iodised evening primrose oil capsule; oral route; once at study start

MNP45 + INERT OIL

Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;

Group Type EXPERIMENTAL

MNP45

Intervention Type DIETARY_SUPPLEMENT

45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

INERT OIL

Intervention Type DIETARY_SUPPLEMENT

Non-iodised evening primrose oil capsule; oral route; once at study start

IODISED OIL + INERT MNP

Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start

Group Type EXPERIMENTAL

IODISED OIL

Intervention Type DIETARY_SUPPLEMENT

200 mg iodine oil capsule; oral route; once at study start

INERT MNP

Intervention Type DIETARY_SUPPLEMENT

Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily

NON-IODISED MNP + INERT OIL

Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.

Group Type ACTIVE_COMPARATOR

INERT OIL

Intervention Type DIETARY_SUPPLEMENT

Non-iodised evening primrose oil capsule; oral route; once at study start

NON-IODISED MNP

Intervention Type DIETARY_SUPPLEMENT

Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MNP90

90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

Intervention Type DIETARY_SUPPLEMENT

MNP45

45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

Intervention Type DIETARY_SUPPLEMENT

IODISED OIL

200 mg iodine oil capsule; oral route; once at study start

Intervention Type DIETARY_SUPPLEMENT

INERT OIL

Non-iodised evening primrose oil capsule; oral route; once at study start

Intervention Type DIETARY_SUPPLEMENT

INERT MNP

Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily

Intervention Type DIETARY_SUPPLEMENT

NON-IODISED MNP

Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages:
* For pilot - aged 6 - 18 months (+2 weeks, no infant \< 6 months)
* For intervention - aged 6 - 9 months (+2 weeks, no infant \< 6 months)
* Born to a healthy singleton pregnancy
* Term (week 38 to 42) delivery
* Family residence at the study site for at least 12 months prior to the start of the study and anticipated residence for at least a further 12 months (mother and infant)
* Exclusively breastfed for at least 2 months, or if not, having received no other sources of iodine intake (in formula, supplements, or foods)
* Signed informed consent

Exclusion Criteria

* Suffering from severe acute malnutrition(\< 3 weight-for-height z-scores)
* Known history of medical illnesses
* Taking chronic medications (mother and infant)
* Use of iodine containing dietary supplements during the last 6 months (mother and infant)
* Exposure to iodine containing X-ray / CT contrast agent, skin disinfectants or medications during the last 6 months (mother and infant)
* Participation in any other clinical study (mother and infant) or participated in the pilot study (infant)

NB: Severe Acute Malnutrition is defined as being below 3 standard deviations (SD) of the WHO standard for weight-for-height ratio for infants and children aged 6 to 60 months. All infants identified with SAM will be excluded from the study and referred to hospital or nutrition clinic for treatment.
Minimum Eligible Age

6 Months

Maximum Eligible Age

9 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UNICEF

OTHER

Sponsor Role collaborator

Global Alliance for Improved Nutrition

OTHER

Sponsor Role collaborator

Swiss Federal Institute of Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael B Zimmermann, MD

Role: PRINCIPAL_INVESTIGATOR

ETH Zuerich

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK-2014-N-35

Identifier Type: OTHER

Identifier Source: secondary_id

EK-2014-N-35

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

An Iodine Balance Experiment
NCT03279315 COMPLETED NA